摘要
目的多囊卵巢综合征(PCOS)是育龄期妇女常见的内分泌紊乱性疾病,胰岛素抵抗(IR)和高胰岛素血症与PCOS发病密切相关,它的家族聚集现象提示遗传因素在PCOS发病机制中起重要作用。尾加压素Ⅱ是一种血管活性肽,在胰岛素抵抗中发挥一定作用。本研究的目的是通过分析尾加压素Ⅱ(UTS2)基因rs228648(A/G)、rs2890565(A/G)的多态性在PCOS患者和正常对照之间基因型和等位基因频率的差异,及PCOS患者杂合子父母不同等位基因有无优势传递,比较不同基因型PCOS病人临床、内分泌及代谢特征的差别,研究相关基因多态性与PCOS不同表型的相关性,以探讨UTS2基因在PCOS发病及病理变化过程中的相关作用。
方法本研究依据2003年鹿特丹标准选择PCOS患者101例及其父母202例,并选择同期就诊的105名健康妇女作为对照组。测定PCOS组及对照组基础状态下卵泡刺激素(FSH)、黄体生成素(LH)、睾酮(T)、空腹血糖(FPG)、胰岛素水平(FINS),测量身高、体重、腰围和臀围,计算体重指数(BMI)、腰臀比例(WHR)及胰岛素抵抗指数(HOMA-IR)。提取其抗凝血的DNA,根据所研究基因的序列设计相应引物,应用PCR扩增相应片段后,用熔解温度不同的基因分型法检测PCOS患者及其父母和对照组尾加压素Ⅱ基因rs228648(A/G)、rs2890565(A/G)的多态性并测序分析。
结果(1)PCOS组与对照组相比,年龄无显著性差异,但PCOS组BMI,WHR高于对照组,LH和T水平也显著高于对照组,差异均有统计学意义;尾加压素Ⅱ基因rs228648A/G多态性在PCOS患者组及其父母组、对照组均符合Hardy-Weinberg平衡定律;PCOS组与对照组比较,基因型频率与等位基因频率均无明显差异;传递不平衡检验(TDT)显示,尾加压Ⅱ素基因rs228648A/G多态性位点杂合子父母2个不同等位基因无优势传递(P>0.05);尾加压素Ⅱ基因的SNPrs228648A/G多态性在PCOS-IR组及NIR组、肥胖组及非肥胖组的基因型分布及等位基因频率均无显著性差异(P>O.05),PCOS组尾加压素Ⅱ基因rs228648(A/G)不同基因型间BMI、WHR、LH、FSH、LH/FSH、TT、FPG、FINS、血脂差异无统计学意义(P>0.05),HOMA-IR在不同基因型间比较,差异有统计学意义(P<0.05)。GG基因型较携带A等位基因的PCOS患者HOMA-IR明显增高(2.33±2.06 vs1.83±1.08,P=0.038)。
(2)尾加压素Ⅱ基因rs2890565A/G多态性在PCOS患者组及其父母组、对照组均符合Hardy-Weinberg平衡定律;SNPrs2890565在PCOS组AA基因型11例(10.89%),AG基因型43例(42.57%),GG基因型46例(46.53%);对照组AA基因型5例(4.76%),AG基因型34例(32.38%),GG基因型66例(62.86%),两组基因型频率比较差异有统计学意义(P<0.05)。PCOS组A等位基因频率(32.18%)明显高于对照组(20.95%),差异有统计学意义(P<0.05)。传递不平衡检验(TDT)显示,尾加压素Ⅱ基因rs2890565A/G多态性位点杂合子父母2个不同等位基因传递概率偏离50%(P<0.05),A等位基因优势传递;尾加压素Ⅱ基因的SNPrs2890565A/G多态性在PCOS-IR组AA+AG基因型频率63.6%,GG基因型36.4%,NIR组AA+AG基因型频率41.3%,GG基因型58.7%,IR组AA+AG基因型频率高于NIR组,两组比较差异有统计学意义(P<0.05)。PCOS-IR组A等位基因频率40.9%,G等位基因频率59.1%,NIR组A等位基因频率21.7%,G等位基因频率78.3%,IR组A等位基因频率显著高于NIR组,差异有统计学意义(P<0.01)。尾加压素Ⅱ基因的SNPrs2890565多态性在肥胖组及非肥胖组的基因型分布及等位基因频率无显著性差异(P>0.05),PCOS组尾加压素Ⅱ基因rs2890565(A/G)不同基因型间BMI、WHR、LH、FSH、LH/FSH、TT、血脂差异无统计学意义(P>0.05),FPG、FINS、HOMA-IR在不同基因型间差异有统计学意义。AA和AG基因型FPG较GG基因型明显增高(5.57±0.72 or 5.36±0.52 vs 4.02±0.59mmol/L,P<0.05),FINS较GG基因型明显增高(14.78±10.40 or11.24±6.13 vs 9.57±5.23 U/L,P<0.05)。AA基因型HOMA-IR较GG基因型明显增高(3.53±2.76 vs1.82±1.25 P<0.05)。
结论(1)UTS2基因SNPrs228648A/G多态性与PCOS的临床特征,内分泌激素水平无相关性,但与胰岛素抵抗存在关联。(2)UTS2基因SNPrs2890565A/G多态性可能与PCOS发病相关,A等位基因与PCOS的胰岛素抵抗有关,与肥胖无密切关系。
目的本研究的目的是通过分析脂联素受体1(ADIPOR1)基因rs1539355A/G多态性在PCOS患者和正常对照之间基因型和等位基因频率的差异,及PCOS患者杂合子父母不同等位基因有无优势传递,比较不同基因型PCOS病人临床、内分泌及代谢特征的差别,研究相关基因多态性与PCOS不同表型的相关性,以探讨ADIPOR1基因在PCOS发病及病理变化过程中的相关作用。
方法本研究依据2003年鹿特丹标准选择PCOS患者101例及其父母202例,并选择同期就诊的105名健康妇女作为对照组。测定PCOS患者及对照组基础状态下卵泡刺激素(FSH)、黄体生成素(LH)、睾酮(T)、空腹血糖(FPG)、胰岛素水平(FINS),测量身高、体重、腰围和臀围,计算体重指数(BMI)、腰臀比例(WHR)及胰岛素抵抗指数(HOMA-IR)。提取其抗凝血的DNA,根据所研究基因的序列设计相应引物,应用PCR扩增相应片段后,用熔解温度不同的基因分型法检测PCOS患者及其父母和对照组脂联素受体1基因rs1539355A/G的多态性并测序分析。
结果(1)脂联素受体1基因rs1539355A/G多态性在PCOS患者组及其父母组、对照组均符合Hardy-Weinberg平衡定律;PCOS组与对照组比较,基因型频率与等位基因频率均无明显差异,传递不平衡检验(TDT)显示,ADIPOR1基因rs1539355位点杂合子父母2个不同等位基因无优势传递(P>0.05);(2)ADIPOR1基因rs1539355A/G多态性在PCOS-IR组AA基因型为30.9%,AG+GG基因型69.1%;PCOS-NIR组AA基因型60.9%,AG+GG基因型39.1%,PCOS-IR组AG+GG基因型频率高于PCOS-NIR组,差异有统计学意义(P<0.05)。PCOS-IR组A等位基因频率61.8%,G等位基因频率38.2%;PCOS-NIR组A等位基因频率78.3%,G等位基因频率21.7%。PCOS组-IR组G等位基因频率高于PCOS-NIR组,差异有统计学意义(P<0.05)。ADIPOR1基因rs1539355A/G多态性在肥胖组与非肥胖组、高雄激素组与非高雄激素组基因型频率及等位基因频率无显著性差异(P>0.05)。(3)携带G等位基因的PCOS患者BMI、HOMA-IR较AA基因型明显升高(26.26±4.09 vs24.13±3.07 kg/m~2, 2.32±1.07 vs1.85±0.56,),差异有统计学意义(P<0.05),经一般线形模型控制BMI的影响后,携带G等位基因的PCOS患者HOMA-IR与AA基因型比较,差异仍有统计学意义(P=0.038)。
结论(1)ADIPORI基因rs1539355A/G多态性可能与PCOS的胰岛素抵抗相关,并对BMI有一定影响。(2)ADIPOR1基因rs1539355A/G多态性与内分泌激素水平,脂代谢水平无相关性。
目的探讨多囊卵巢综合征(PCOS)患者糖耐量受损(IGT)和糖尿病(NIDDM)的发生率及其高危因素。
方法采用回顾性分析的方法,对101例PCOS患者行口服葡萄糖耐量(OGTT)实验后的临床资料进行分析,多因素logistic回归分析方法探讨PCOS患者糖耐量异常的危险因素。
结果(1)根据葡萄糖耐量实验结果分成糖耐量异常组(AGT)24例(IGT22例、NIDDM2例)与糖耐量正常组(NGT)77例,IGT发生率21.8%,NIDDM发生率1.98%。(2)AGT组与NGT组相比,年龄、腰臀比(WHR)、体重指数(BMI)、睾酮、空腹血糖(FPG)、2小时血糖增高,差异有统计学意义(P<0.05),空腹胰岛素(FINS)、2小时胰岛素、稳态模式胰岛素抵抗指数(HOMA-IR)升高,差异具有统计学意义(P<0.01)。初潮年龄、黄体生成素/卵泡刺激素(LH/FSH)两组比较,差异无统计学意义(P>0.05)。(3)糖耐量异常组一级亲属有糖尿病家族史者15例,占62.5%(15/24),糖耐量正常组一级亲属有糖尿病家族史者24例,占31.2%(24/77),两组比较,糖耐量异常组一级亲属有糖尿病家族史者发生率明显增高,差异有统计学意义(P<0.01)。(4)多因素logistic回归分析显示,年龄、BMI、2型糖尿病家族史、空腹胰岛素为PCOS糖耐量异常的高危因素。
结论多囊卵巢综合征发生糖耐量受损、糖尿病的危险性增加,葡萄糖耐量2小时血糖水平是PCOS糖耐量异常的较好监测指标。年龄、BMI、2型糖尿病家族史、空腹胰岛素是PCOS糖耐量异常发生的危险因素。
Objective Polycystic ovary syndrome (PCOS) is one of the most common endocrine diseases of women of fertile age. Insulin resistance (IR) has a crucial role in the pathogenesis of this disorder. There is evidence for a genetic component in PCOS based on familial clustering of cases . UrotensinⅡhas been found to be a potent vasoactive peptide in humans and may be implicated in the development of insulin resistance. The objective of this study was to investigate the distribution of the single nucleotide polymorphisms of rs228648 and rs2890565 in urotension 2(UTS2) gene in PCOS patients and controls in a Chinese population , to reveal biased transmission of two different allels from heterozygous parents to affected daughters,to analyze the association of two single nucleotide polymorphisms with the clinical, the hormone and metabolic characteristics of PCOS, and to evaluate genetic influence of the two SNPs of UTS2 gene on the development of PCOS.
Methods 101 Chinese Han families trios consisting of fathers , mothers, affected daughters with PCOS are recruited .The affected patients with PCOS were recruited according to the revised diagnostic criteria, announced in the 2003 American Society for Reproductive Medicine/European Society for Human Reproduction and Embryology (ASRM/ESHRE) Roterdam consensus. 105 women were selected as healthy controls. The physiological and biochemical parameters including height,weight, abdominal and hip circumference, levels of serum follicular stimulating hormone (FSH), luteinizing hormone (LH), testosterone, fasting glucose and insulin are measured. DNA was extracted from human leukocyte nuclei isolated from whole blood. The genotypes of rs228648 and rs2890565 in urotensionⅡgene were determined through polymerase chain reaction Tm-shift genotyping method and were further confirmed by DNA sequence analyses.
Results (1)There is no significant difference in age between the PCOS patient and the control groups. The levelof T ,LH,BMI,and WHR is significantly higher in the PCOS group than that in control group.The distribution of genotypic frequency of SNP rs228648 in controls, PCOS group and their parents group did not deviate from the Hardy-Weinberg equilibrium; The distribution of three genotype and two allelotypes of SNP rs228648 in urotension gene were similar between PCOS group and control group. Transmission disequilibrium test ( TDT)did not show significantly biased transmission of two different allels from parents to affected daughters at rs228648 locus( P > 0.05); No significant differences between the distributions of the SNP rs228648 polymorphisms were observed when PCOS-IR group and PCOS-NIR group were compared The same results were found in obese PCOS women compared to non-obese PCOS women. There was no significant difference of clinical, hormone,lipids metabolism characteristics of different genenotype of the SNP rs228648 in PCOS women , but the carriers with GG genotype of SNP rs228648(A/G) had significantly higher HOMA-IR compared to those with AA and AG genotypes( 2.33±2.06 vsl.83±1.08,P=0.038).
(2) The distribution of genotypic frequency of SNP rs2890565 in PCOS group and their parents group and control group did not deviate from the Hardy-Weinberg equilibrium; The frequency of AA,AG,GG genotype of SNP rs2890565 in PCOS group was 10.89%, 42.57%,46.53% respectively, while in control group was4.76%, 32.38%,62.86% respectively. The distribution of genotype of SNP rs2890565 in urotension gene differed significantly between PCOS group and control group (P<0.05) .The frequency of A allele in PCOS group and control group was 32.18%,20.95%, while G allele was 67.82%,79.05%. The frequency of A allele of SNP rs2890565 in urotension gene was significantly higher in PCOS group than in control group (P<0.05) .TDT analysis showed an excess of A allele from heterozygous parents to affected offspring (P<0.05). The frequency of AA+AG genotype of SNP rs2890565 in PCOS-IR group and PCOS-NIR group was 63.6%, 41.3% respectively, while GG genotype was36.4%,58.7% respectively. The distribution of genotype of SNP rs2890565 in urotension gene differed significantly between PCOS-IR group and PCOS-NIR group (P<0.05) .The frequency of A allele in PCOS-IR group and PCOS-NIR group was 40.9%,21.7%, while G allele was 59.1%,78.3%. The distribution of two alleles of SNP rs2890565 in urotension gene was different between PCOS-IR group and PCOS-NIR group (P<0.05) . There was no significant difference of hormone,lipids metabolism characteristics of different genenotype of the SNP rs2890565 in PCOS women ,but the carriers with AA or AG genotype of SNP rs2890565(A/G) had significantly higher fasting plasma glucose(5.57±0.72 or 5.36±0.52 vs 4.02±0.59mmol/L, PO.05), higner fasting insulin(14.78±10.40 or 11.24±6.13 vs 9.57±5.23 U/L, P<0.05 ) compared to those with GG genotypes . HOMA-IR with AA genotype was significantly higher than those with GG genotype (3.53±2.76 vsl.82±1.25 P<0.05) .
Conclusions There was no association of SNP rs228648 with clinical,hormone characteristics in PCOS women, but was found to be associated with insulin resistance in PCOS women. The genetic polymorphism of urotensionⅡgene rs2890565(A/G) may be associated with PCOS , the higher frequency of A allele was associated with insulin resistance in PCOS but had no association with obesity.
Objective The objective of this study was to investigate the distribution of the single nucleotide polymorphism of rsl539355 in adiponectin receptor 1(ADIPOR1) gene in PCOS patients and controls in a Chinese population , to reveal biased transmission of two different allels from parents to affected daughters,to analysis the association of the single nucleotide polymorphism with the clinical, the hormone and metabolic characteristics of PCOS, and to evaluate genetic influence of the SNP of ADIPOR1gene on the development of PCOS.
Methods 101 Chinese Han families trios consisting of fathers , mothers, affected daughters with PCOS were recruited .The affected patients with PCOS were recruited according to the revised diagnostic criteria, announced in the 2003 American Society for Reproductive Medicine/European Society for Human Reproduction and Embryology (ASRM/ESHRE) Roterdam consensus. 105 women were selected as healthy controls .The physiological and biochemical parameters including height,weight, abdominal and hip circumference, levels of serum follicular stimulating hormone (FSH), luteinizing hormone (LH), testosterone, fasting glucose and insulin were measured. DNA was extracted from human leukocyte nuclei isolated from whole blood. The genotypes of rs1539355 locus in ADIPOR1 gene were determined through polymerase chain reaction Tm-shift genotyping method and were further confirmed by DNA sequence analyses.
Results There was no significant difference in age between the PCOS patients and the control group . The levelof T ,LH,BMI,and WHR was significantly higher in the PCOS group than that in control group.The distribution of genotypic frequency of SNP rs1539355 in controls, PCOS group and their parents group did not deviate from the Hardy-Weinberg equilibrium; The distribution of three genotype and two allelotypes of SNP rs1539355 inADIPOR1 gene were similar between PCOS group and control group. Transmission disequilibrium test ( TDT) did not show significantly biased transmission of two different allels from parents to affected daughters at rs1539355 locus( P > 0.05); (2) The frequency of AG+GG genotype of SNP rsl539355 in PCOS-IR group and PCOS-NIR group was 69.1%, 39.1% respectively, while AA genotype was30.9%,60.9% respectively. The distribution of genotype of SNP rsl539355 in urotension gene differed significantly between PCOS-IR group and PCOS-NIR group(P<0.05) .The frequency of A allele in PCOS-IR group and PCOS-NIR group was 61.8%,78.3%, while G allele was 38.2%,21.7%. The distribution of two alleles of SNP rs1539355 in ADIPOR1 gene were different between PCOS-IR group and PCOS-NIR group (P<0. 05) . The distribution of frequency of genotypes and alleles was similar in hyperandrogenism group and non- hyperandrogenism group,obese group and non-obese group (3) The carriers with G allele had higher body mass index (BMI) ( P<0. 05) and HOMA-IR ( P <0. 05) compared to AA genotype in the patients with PCOS.(26. 26±4.09 vs24. 13±3. 07 kg/m~2, 2.32±1.07 vs1. 85±0. 56) . A univariate general linear model analysis, introducing BMI as a covariate in the model, was perfomed , the results showed that SNP rsl539355 still influenced HOMA-IR( P <0.05).
Conclusions SNP rs1539355 in ADIPOR1 gene was found to be associated with insulin resistance and had some influence on BMI, but there was no association with hormonal and lipid characteristics in PCOS women.
Objective To analyse the prevalence of impaired glucose tolerance (IGT) and diabetes mellitus(NIDDM) in women with polycystic ovary syndrome and to identify associated risk factors within this population.
Method Retrospective study was performed in 101 women with PCOS and clinical data were analysed after oral glucose tolerance tests to identify risk factors for abnormal glucose tolerance by using multivariate logistic regression.
Results Based on the criteria for IGT and NIDDM, PCOS women were divided into two groups :77 cases with normal glucose tolerancr(NGT) and 24 cases with abnormal glucose tolerance. The prevalence for IGT was 21.8% and that of NIDDM was 1.98%. The mean age, body mass index(BMI), waist hip ratio(WHR), total testosterone, fasting plasma glucose, 2-h plasma glucose level were significantly different between AGT and NGT group(P<0.05). Fasting insulin, 2-h insulin, homeostasis model assessment of insulin resistance were significantly higher in AGT group(P＜0.01). Menarche age and LH/FSH made no difference between the two groups(P>0.05). The incidence of a family history of diabetes was higher in AGT patients(P<0.01). Multivariate logistic regression showed that age, BMI, , a family history of diabetes,fasting insulin levels were independent risk factors for AGT.
Conclusion Women with PCOS are at increased risks for abnormal glucose metabolism. 2-h plasma glucose level after oral glucose toerance test was a significant predictor for abnormal glucose tolerance in women with PCOS. Age, BMI, a family history of diabetes, fasting insulin levels were independent risk factors for abnormal glucose tolerance.
引文
1.Gonzalez A, Saez ME, Aragon ML et al. Specific haplotypes of the CALPAIN-5 gene are associated with polycystic ovary syndrome.Hum Reprod. 2006 Apr;21(4):943-951.
2.Burghen GA,G ivens JR, Kitabchi AE.Correlation of hyperandorgenism with hyper insulinism in polycystic ovarian disease. J Clin Endocrinol M etab,1980;50
3.Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.Fertil Steril,2004;8 1(1):19 -25.
4.Lobo RA and Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med, 2000,132,989-993.
5.Diamanti-K,Andarakis E,Dunaif A. New perspectives in polycystic ovary syndrome.Trends Endocrinol,1996,7:267-271.
6.Dunaif A, Wit X, LeeA, et al.Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome.Clin Endocrinol Metab,2001,28(2):392-399.
7.MarsdcnPJ, Muldoch AP,TaylorR.Tissue insulin sensitivity and bodyweight in polycystic ovary syndrome.ClinEndocrinol, 2001,55(2): 191-199
8.Azziz R. Polycystic ovary syndrome, insulin resistance, and molecular defects of insulin signaling. J Clin EndocrinolMetab, 2002, 87: 4085-4087.
9.Park KH, Kim JY, Ahn CW, et al. Polycystic ovarian syndrome( PCOS) and insulin resistance. Int J Gynaecol Obstet, 2001, 74: 261-267.
10.朱雅男,王勇,吴效科.多囊卵巢综合征胰岛素抵抗的分子机制.中国实用妇科与产科杂志2005,21(8):305-308
11.Nestler JE,Jakubowicz DJ,de Vargas AF,et al.Insulin stimulates testosterone biosynthesis by human theca cells from women with polycystic ovary syndrom by activating its own receptor and using inositoglycan mediators as the signal transduction system.J Clin Endocrinol Metab,1998,83:2001-2005.
12.Franks S,Robinson S,Wilis DS,et al.Nutrition,insulin and polycystic ovary syndrom .Rev Reprod 1996,1:47-53.
13.Giling-smith C,Willis DS,Beard RW,et al.Hypersecretion of androstenedione by isolated theca cells from polycystic ovaries.J Clin Endocrinol Metab,1994, 79; 1158-1165
14.Hiller SG,Tetsuka M.Role of androgens in follicle maturation and atresia.Baillierves Clin Obstet Gynaecol, 1997,11:249-260.
15. Paradisi G, Steinberg HO. polycystic ovary syndrome is associated with endothelial dysmction.Circulation, 2001,103(10): 1410-1405.
16.Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ, et al. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contracep tive p ills. J Clin Endocrinol Metab, 2003, 88: 1927-1932.
17. BaRcellos CR, Rocha MP, Hayashida SA,et al. Prevalence of abnormalities of glucose metabolism in patients With polycystic ovary syndrom. Arq Bras Endocrinol Metab. 2007,51:601-605
18.Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-169.
19.EhrmannD A,B arnesR B,Rosenfield RL,et al.Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.Diabetes Carel999,22(1):141-146,
20.Ames RS, Sarau HM, Chambers JK, et al. Human urotensin II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 . Nature, 1999, 401: 282-286.
21.Elshourbagy NA, Douglas SA, Shabon U, et al .Molecular and pharmacological characterization of genes encoding urotensin II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol , 2002,136:9-22.
22.Yamauchi T, Kamon J, Ito Y, et al . Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature ,2003 ,423 :762-769.
23.Kharroubi I,Rasschaert J,Eizirik DL,et al.Expression of adiponectin receptors in pancreatic beta cells. Biochem Biophys Res Commun.2003,312:l 118-1122
24.Damcott CM,Ott SH,Pollin TI,et al.Genetic variation in adiponectin receptor 1 and adiponectin receptor 2 is associated with the old order Amish.Diabetes. 2005,54(7);2245-2250.
1.陈子江.高度重视多囊卵巢综合征的规范化诊断与治疗.中华妇产科杂志.2007,42(5):289-290.
2.Vincent MA,Cler RE, Rattigan S,et al.Active role for the vasculature in the delivery of insulin to skeletal muscle.Clin Exp Pharmacol Physiol,2005,32:302-307
3.Baron AD. Insulin resistance and vascular function. Diabetes Complications ,2002,16:92-102.
4.Ames RS, Sarau HM, Chambers JK, et al. Human urotensin II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 . Nature, 1999, 401:282-286.
5.Wilkes JJ, Hevener A, Olefsky J. Chronic endothelin-1 treatment leads to insulin resistance in vivo. Diabetes2003;52:1904-1909.
6.Silvestre RA ,Rodriguez-Gallardo J ,Egido EM,et al. Inhibition of insulin release by urotensin Ⅱ-a study on the perfused rat pancreas. Horm Metab Res ,2001 ,33:379-381.
7.祝方,纪立农,罗斌.硬骨鱼紧张素Ⅱ基因多态性与中国人2型糖尿病遗传易感性的关系.中华医学杂志,2002,82:1472-1475.
8.Suzuki S, Wenyi Z, HiraiM, et al.Genetic variations at urotensin Ⅱ and urotensin Ⅱ receptor genes and risk of type 2 diabetes mellitus in Japanese. Peptides, 2004, 25:1803-1808.
9.The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.Revised 2003 consensuson diagnosis criteria and long-term health risks related to polycystic ovary syndrome(PCOS). Hum Reprod,2004,19(1): 41
10.De Paula Martins W,Santana LF,Nastri CO et al. Agreement among insulin sensitivity indexes on the diagnosis of insulin resistance in polycystic ovary syndrome and ovulatory women. Eur J Obstet Gynecol Reprod Biol.2007 ;133:203-207.
11. Wang J,Chuang K,Ahluealia M,et al.High-throughput SNP genotyping by single-tube PCR with Tm-shift primers.Biotechniques,2005,39:885-893
12. Papp AC,Pinsonneault JK,Cooke G, et al.Single nucleiotide polymorphism genotyping using allele-specific PCR and fluorescence melting curves.Biotechniques,2003,34:1068-1072
13. Elshourbagy NA ,Douglas SA ,Shabon U ,et al .Molecular and pharmacological characterization of genes encoding urotensin II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br J Pharmacol ,2002,136:9-22.
14. Do-Rego JC, Chatenet D, Orta MH, et al. Behavioral effects of urotensin-Ⅱ centrally administered in mice. Psychopharmacology (Berl) 2005; 183:103-117.
15. Cheung BM, Leung R, Man YB, et al. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 2004;22:1341-1344.
16. Silvestre RA, Egido EM, Hernandez R, et al. Urotensin-Ⅱ is present in pancreatic extracts and inhibits insulin release in the perfused rat pancreas. Eur J Endocrinol 2004; 151:803-809.
17. Silvestre RA, Rodriguez-Gallardo J, et al.Inhibition of insulin release by urotensin Ⅱ-a study on the perfused rat pancreas. Horm Metab Res 2001 ;33: 379-381.
18. Watson AM, Lambert GW, Smith KJ, May CN. Urotensin Ⅱ acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 2003;42:373-379o
19. Silvestre RA ,Rodriguez-Gallardo J ,Egido EM,et al . Inhibition of insulin release by urotensin Ⅱ-a study on the perfused rat pancreas. Horm Metab Res ,2001,33:379-381.
20. 彭公永,何志义,刘启才,等.尾加压素Ⅱ促兔肺动脉平滑肌细胞增殖及机理探讨.中国病理生理杂志,2004,20:1597-1600.
21. Johns DG, Ao Z, Naselsky D, Herold CL, et al. Urotensin-Ⅱ-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 2004;370: 238-250.
22. Djordjevic T, BelAiba RS, Bonello S, et al. Human urotensin Ⅱ is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vase Biol 2005;25: 519-525.
23. Mallamaci F, Cutrupi S, Pizzini P,et al. Urotensin Ⅱ and biomarkers of endothelial activation and atherosclerosis in end-stage renal disease. Am J Hypertens2006;19:505-510.
24. 孙红霞,杜玮南,左瑾,等.蛋白激酶Cζ亚型基因及UrotensinⅡ基因中各有一个单核苷酸位点与中国北方汉族人群2型糖尿病相关。中国医学科学院学报,2002,24:223-227.
25. Wenyi Z, Suzuki S, HiraiM, et al. Role of urotensin Ⅱ gene in genetic suscep tibility to Type 2 diabetes mellitus in Japanese subjects. Diabetologia, 2003, 46:972-976.
26. Ong KL,Wong L,Bun Man,et al.Haplotypes in the urotension Ⅱ gene and urotension Ⅱ receptor gene are associated with insulin resistance and impaired glucose tolerance.Peptides,2006,1659-1667.
27. George Thao T, Adel H, Giaid. Urotensin Ⅱ and cardiovascular diseases .Peptides2004 ,25 :1789-1794
28. Jiang I,Michal,JJ,Tobey DJ,et al.Comparative understanding of UTS2 and UTS2R genes for their involvement in type 2diabetes mellitus.Int J Biol Sci.2008,4(2):96-102.
29. Gonzalez A,Abril E,Roca,et al.Comment:CAPN10 alleles are associated with polycystic ovary syndrome.J Clin Endocrinol Metab,2002.87:3971-3976
30. Haddad L,Evabs JC,Gharani N,et al.Variation within the type 2 diabetes susceptibility gene calpain 10 and polycystic ovary syndrome. J Clin Endocrinol Metab,2002.87:2606-2610
31. Thamas soulis G, Huyhn T, Giaid A,et al.Urotension Ⅱ and vascular disease.Peptides,2004;25(10):1789-1794.
32. Ong KL,Wong LY,Cheung BM.The role of Urotension Ⅱ in the metabolic syndrome.Peptides.2008,29(5):859-867.
33. WatanabeT, Kanome T, Suguro T,et al. Human urotension II and metablic syndrome.Vsacular Disease Prevention.2006;3:91～98
34. Ovalle F, Azziz R. Insulin resistance, polyeystic ovary syndrome, and type 2 diabetes mellitus .Fertil Steril,2002,7 7(6): 1095-1105.
1. Kelestimur F, Unluhizarci K, Baybuga H, et al. Prevalence of polycystic ovarian changes and polycystic ovary syndrome in premenopausal women with treated type 2 diabetes mellitus. Fertil Steril 2006;86:405-410.
2. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005;83:1454-1460.
3. Pelusi B, Gambineri A, Pasquali R. Type 2 diabetes and the polycystic ovary syndrome. Minerva Ginecol 2004;56:41-51.
4. Roldan B, San Millan JL, Escobar-Morreale HF. Genetic basis of metabolic abnormalities in polycystic ovary syndrome: implications for therapy. Am J Pharmacogenomics 2004;4: 93-107.
5. Orio F, Palomba S, Cascella T, et al. Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:2619-2623.
6. Panidis D, Kourtis A, Farmakiotis D, Mouslech T, Rousso D, Koliakos G Serum adiponectin levels in women with polycystic ovary syndrome. Hum Reprod 2003; 18:1790-1796.
7. Matsubara M,Maruokas S,Katayose S,et al. Decreased plasma adiponectin concentrations in women with dyslipidemia.J Clin Endocrinol Metab,2002, 86:2764-2769.
8. Zhang N,Shi YH, Hao CF,et al.Association of +45G15G(T/G) and +276(G/T) polymorphisms in the ADIPOQ gene with polycystic ovary syndrome among Han Chinese women.Eur J Endocrinol.2008,158(2):255-260
9. Nakatani K Noma K, Nishioka J. Adiponectin gene variation associates with the increasing risk of type 2 diabetes in non-diabetic Japanese subjects. Int J Mol Med.2005;15(1):173-177.
l0.Menzaghi C, Ercolino T, Di Paola R et al. A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 2002,51:2306-2312.
11. Gibson F, Froguel P. Genetics of the APM1 locus and its contribution to type 2 diabetes susceptibility in French Caucasians. Diabetes 2004;53:2977-2983.
12. Qi L, Li T, Rimm E et al .The +276 polymorphism of the APM1 gene, plasma adiponectin concentration, and cardiovascular risk in diabetic men. Diabetes 2005;54:1607-1610.
13. Yamauchi T ,Kamon J ,Ito Y,et al . Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature ,2003 ,423 :762-769.
14. Tsuchida A, Yamauchi T, Ito Y,et al. Insulin/ Foxol pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem,2004 , 279:30817-30822.
15. Quchi N,Kihara S,Arita Y,et al.Adiponetin, an adipocyte-derived plasma protein, inhibites endothelial NF-kB signaling through a cAMP-dependent pathway. Circulation, 2000,102:1296-1301
16. Civitarese AE ,Jenkinson CP ,Richardson D ,et al . Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of type 2 diabetes. Diabetologia, 2004,47 :816-820.
17. Staiger H ,Kaltenbach S ,Staiger K,et al . Expression of adiponectin receptor mRNA in human skeletal muscle cells is related to in vivo param eters of glucose and lipid metabolism. Diabetes ,2004 ,53 :2195-2201.
18. Bluher M,Bullen Jr Jw,Lee JH. Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle:associations with metabolic parameters and insulin resistance and regulation by physical training.J Clin Endocrinol Metab,2006,91:2310-2316.
19. Damcott CM,Ott SH,Pollin TI,et al.Genetic variation in adiponectin receptor 1 and adiponectin receptor 2 is associated with the old order Amish. Diabetes, 2005, 54(7);2245-2250
20. De Paula Martins W,Santana LF,Nastri CO et al. Agreement among insulin sensitivity indexes on the diagnosis of insulin resistance in polycystic ovary syndrome and ovulatory women. Eur J Obstet Gynecol Reprod Biol.2007 ; 133:203-207.
21.Kharroubi I,Rasschaert J,Eizirik DL,et al.Expression of adiponectin receptors in pancreatic beta cells.Biochem Biophys Res Commun.2003,312:l 118-1122
22.Kadowaki T,Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome.J Clin Invest 2006 ; 116:1784-1792.
23.Tan BK, Chen J, Diqby JE,et al. Upregulation of adiponectin receptor land 2 mRNA and protein in adipose tissue and adipocytes in insulin-resistant women with polycystic ovary syndrome.Diabetoloqia,2006,49(11):2723-2728
24.Ruchat SM,Loose RJ,Rankinen T,et al.Associations between glucose tolerance,insulin sensitivity and insulin secretion phenotypes and polymorphisms in adiponectin and adiponectin receptor genes in the Quebec Family Study.Diabet Med,2008,25(4):400-406
25.Siitonen N,Pulkkien L,Maqeru,et al.Association of sequence variations in the gene encoding adiponectin receptor l(ADIPOR1) with body size and insulin levels.The Finnish Diabetes Prevention Study.Diabetologia.2006,49(8): 1795-1805.
26.胡承,贾伟平,张蓉，脂联素受体1基因-3881T/C多态位点与中国人糖代谢的关系.中华医学遗传学杂志,2007,24:27-30
27.Collins SC,Luan J,Thompson AJ,et al.Adiponectin receptor genes: mutation screening in syndromes of insulin resistance and association studies for type 2 diabetes and metabolic traits in UK populations. Diabetologia 2007 ;50:555-562.
28.Stefan N,Machicao F,Staiger H,et al. Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat.Diabetologoa.2005 Nov;48(11):2282-2291.
29.Vink JM,Sadrzadeh S,Lambalk CB et al. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab 2006;91:2100-4
30.Lu Q,Doria A,Giorgi E,et al.Variation in adiponectin receptor genes and susceptibility to type 2 diabetes in women.Diabetes.2007,56:
31.Wang H, Zhang H,Jia Y,et al.Adiponectin receptor 1 gene (ADIPOR1) as a candidate for type 2 diabetes and insulin resistance. Diabetes.2004 Aug;53(8):2132-2136.
1.陈子江,赵君利,周凤荣,等.济南市汉族育龄妇女PCOS患病状况的初步调查.现代妇产科进展,2005,14(6):442-444.
2. Dabadghao Preeti, Roberts BJ, Wang Jim, et al. Glucose tolerance abnormalities in Australian women with polycystic ovary syndrome. Bioterrorism, 2007,187:328-331
3. BaRcellos CR, Rocha MP, Hayashida SA,et al. Prevalence of abnormalities of glucose metabolism in patients With polycystic ovary syndrom. Arq Bras Endocrinol Metab.2007,51:601-605
4. Bhattacharya SM.Abnormal glucose tolerance in polycystic ovary syndrome. J Obstet Gynaecol Res,2008 ,34:228-232
5. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.Revised 2003 consensuson diagnosis criteria and long-term health risks related to polycystic ovary syndrome(PCOS). Hum Reprod,2004,19: 41
6. Chen XL,Yang DZ,Li L,etal.Abnormal glucose tolerance in Chinese women with polycystic ovary syndrome .Human Reproduction,2006,21:2027-2032
7. Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab, 1999,84:165-169
8. Shi YH, Guo M,Yan J,et al. Analysis of clinial characteristics in large-scale Chinese women with polycystic ovary syndrome. Neuro Endocrinol Lett,2007, 28:807-810
9. Salley KE,Wickham EP,Cheang KI,et al.Position statement:glucose intolerance in polycystic ovary syndrome-a position statement of the androgen excess society. J Clin Metab,2007,92(12)4546-4556.
10. Palmet MR,Gordon CM,Kartashor AI,et al.Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome.J Clin Endocrinol Metab,2002,87:1017-1023.
11. Norman RJ, Masters L, Miner CR,et al. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovary syndrome.Hum Reprod,2001,16:1995-1998.
12.Gambineri A, Pelusi C, Manicardi E, et al. Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome. Diabetes,2004, 53:2353-2358
13.Ehrmann DA,Barnes RB,Rosenfield RL,et al .Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.Diabetes Care,1999,22:141-146.
14.Ehrmann DA, Kasza K, Azziz R, et al. Effects of race and family history of type 2 diabetes on metabolic status of women with polycystic ovary syndrome. J Clin Endocrinol Metab,2005,90:6-71
15.Mohlig M,Spranger J ,Ristow M, et al.Predictors of abnormal glucose metabolism in women with polycystic ovary syndrome. Eur J Endocrinol.2006 Feb;154(2):295-301
16.Weerakiet S,Tingthanatikul Y, Boonnag P,et al. Can adiponectin predict abnormal glucose tolerance in Thai women with polycystic ovary syndrome? J Obstet Gynaecol Res. 2008 34(1):55-61
17.赵君利,陈子江,赵力新,等.血清性激素结合球蛋白与多囊卵巢综合征糖代谢的相关研究.实用妇产科杂志,2005,21:608-611
1.Sam S,Coviello AD,Sung YA,etal.Metabolic phenotype in the brothers of women with polycystic ovary syndrome.Diabetes Care.2008,31(6):1237-1241
2.Sam S,Legro RS,Essah PA,et al.Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome.Proc Natl Acad Sci USA,2006,1003:7030-7035
3.Leibel NI, Baumann EE, Kocherginsky M, et al. Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome . J Clin Endocrinol Metab, 2006,91(4): 1275-1283.
4.Vink JM, Sadrzadeh S, Lambalk CB, et al. Heritability of polycystic ovary syndrome in a Dutch twin-family study . J Clin Endocrinol Metab, 2006,91(6): 2100-2104.
5.Carey AH,Chan KL,ShortF, et al .Evidencefor a single gene effect causing polycystic ovaries and male pattern baldness. Clin Endocrinol,1993,38:653-658
6.Waterworth DM, Bennett ST, Gharani N, et al. Linkage and association of Insulin geneV NTR regulatory polymorphism withp olycystico varys yndrome. Lancet. 1997,349(9057):986-990.
7.Powell BL, Haddad L, Bennett A, et al. Analysis of multiple data sets reveals no association between the insulin gene variable number tandem repeat element and polycystic ovary syndrome or related traits . J Clin Endocrinol Metab, 2005, 90:2988-2993.
8.J in L, Zhu X M, Luo Q, et al. A novel SN P at exon 17 of INSR is associated w ith decreased insulin sensitivity in Chinese women w ith PCOS . M olecular Human Rep roduction, 2006,12 (3): 151-155.
9.陈子江,石玉华,赵跃然,等.胰岛素受体基因多态性与多囊卵巢综合征发病的关系.中华妇产科杂志.2004,39(9):582-585
10.Ehrmann DA, Tang X, Yoshiuchi I, et al. Relationship of insulin receptor substrate-1 and-2 genotypes to phenotypic features of polycystic ovary syndrome. J Clin EndocrinolMetab, 2002, 87: 4297-4300.
11.Hara M , Alcoser S Y, Qaadir A , et al. Insulin resistance is attenuated in women wit h polycystic ovary syndrome with the Pro 12Ala polymorphism in the PPAR Y gene. J Clin Metab, 2002 ,87 (2) :772 - 775.
12. Kor honen S , Heinonen S , Hiltunen M , et al . Polymorphism in the peroxisome proliferator-activated receptor- Y gene in women with polycystic ovary syndrome. Hum Rep rod, 2003 ,18 (3) :540 - 543.
13. Orio FJ , Matarese G , Di BS , et al . Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome. J Clin Endocrinol Metab ,2003 , 88 (12) :5887 - 5892.
14. HaapM ,M achicaoF ,S tefanN ,et al . Genetic determinants of insulin action in polycystic ovary syndrome.Exp Clin Endocrinol Diabetes.2005,113(5): 275- 281
15. Xita N, Georgiou 1, Chatzikyriakidou A, et al. Effect of adiponectin gene polymorphisms on circulating adiponectin and insulin resistance indexes in women with polycystic ovary syndrome.Clin Chem.2005,51 (2):416-423.
16. Wiltgen D, Furtado L, Kohek MB, et al. CAPN10 UCSNP-43, UCSNP-19 and UCSNP-63 polymorphisms and metabolic syndrome in polycystic ovary syndrome .Gynecol Endocrinol, 2007, 23( 3): 173-178.
17. 刁兴华,石玉华,高芹,等.钙蛋白酶10基因多态性与多囊卵巢综合征患者糖耐量及脂代谢异常的相关性.中华妇产科杂志,2008,43(2):106-109
18. Diamanti- Kandarakis E, Bartzis MI, Bergiele AT, et al. Microsatellite polymorphism ( tttta) ( n) at- 528 base pairs of gene CYP11 alpha influences hyperandrogenemia in patients with polycystic ovary syndrome. Fertil Seril, 2000,73(4):735-741.
19. Gaasenbeek M, Powell BL, Sovio U, et al. Large-scale analysis of the relationship between CYP11A promoter variation , polycystic ovarian syndrome, and serum testosterone. J ClinEndocrinolMetab, 2004, 89( 5): 2408-2413.
20. Hector FEM, M anuel LR, Jose L SM. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome . Endocrine Reviews, 2005,26 (2): 251-282.
21. Mifsud A, Ramirez S, Yong EL. Androgen receptor gene CAG trinucleotide repeats in anovulatory infertility and polycystic ovaries.J C lin Endocrinol M etab,2 000;8 5(9):34 84 -3488.
22. Mohlig M, Jurgens A, Spranger, et al. The androgen receptor CAG repeat modifis the impact of testosterone on insulin resistance in women with polycystic ovary syndrome.E ur J Endocrinol,2006;155(l):127-130
23. 赵君利,陈子江,赵跃然,等.性激素结合球蛋白基因启动子(TAAAA)n重复多态及其血清水平与山东地区汉族多囊卵巢综合征糖代谢的关联性.中华医学遗传学杂志,2005,22(6):644-647.
24. Cousin P, Calemard-ML, Lejeune H, et al. Influence of SHBG gene pentanucleotide TAAAA repeat and D327N polymorphism on serum sex hormone-binding globulin concentration in hirsute women . J Clin Endocrinol Metab, 2004, 89(2): 917-924.
25. Tapanainen JS,Koivunen R, FauserB C,et al .A new contributing factor to polycystic ovary syndrome: the genetic variant of luteinizing hormone. Clin Endocrinol Metab, 1999;84 (5): 1711-1715.
26. Yan T,Wu XL,Roy AC, et al .Association of Acc I polymorphism in the FSH β gene with PCOS[J].Fertil Steril, 2000 ,74 (6) :233-236
27. Puder JJ, Varga S, Nusbaumer CP, et al. Women with polycystic ovary syndrome are sensitive to the TNF-alpha-lowering effect of glucose-induced hyperinsulinaemia. Eur J Clin Invest, 2006, 36( 12): 883-889.
28. Vgontzas AN,Trakada G, Bixler EO, et al. Plasma interleukin 6 levels are elevated in polycystic ovary syndrome indepedently of obesiy or sleep apnea.Metabolism,2006,55:1076-1082
29. Diamanti-Kandarakis E, Palioniko G, Alexandraki K, et al. The revalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol,2004,150:793-798.
30. 赵君利,陈子江,赵跃然,等.纤溶酶原激活物抑制因子1基因启动子区4G和5G多态基因型分布与多囊卵巢综合征的相关性研究.中华妇产科杂志,2005,40(8):528-531.
1. Lin TC, Yen JM, Gong KB.Abnormal glucose tolerance and insulin resistance in polycystic ovary syndrome amongst the Taiwanese population- not correlated,with insulin receptor substrate-1 Gly972Arg/Ala513Pro polymorphism. BMC Med Genet. 2006 Apr 7;7:36
2. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005;83:1454-1460.
3. Legro RS, Driscoll D, Strauss JF III, Fox J and Dunaif A . Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA, 1998,95,14956-14960
4.Balen A. The pathophysiology of polycystic ovary syndrome: tyring to understand PCOS and its endocrinology. Best Pract Res Clin Obstet Gynaecol 2004, 18:685-706.
5. Legro RS, Driscoll D, Strauss JF, et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA. 1998; 95:14956-60.
6. Kahsar-Miller MD, Nixon C, Boots LR, et al. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril. 2001;75:53-58.
7. Bern HA, Pearson D, Larson BA. et al. Neurohormones from fish tails: the caudal neurosecretory system. I. "Urophysiology" and the caudal neurosecretory system of fishes. Recent Prog Horm Res. 1985;41:533—552.
8. Bohm F, Pernow J. Urotensin II evokes potent vasoconstriction in humans in vivo. Br J Pharmacol 2002; 135: 25 - 27.
9. Marchese A, Heiber M, Nguyen, T. et al. Cloning and chromosomal mapping of three novel genes, GPR9, GPR10, and GPR14, encoding receptors related to interleukin 8, neuropeptide Y, and somatostatin receptors. Genomics. 1995; 29(2):335-344.
10. Ames RS, Sarau HM, Chambers JK. et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999; 401(6750):282-286.
11 .Watanabe T, Arita S, Shiraishi Y ,et al.Human Urotensin II Promotes Hypertension and Atherosclerotic Cardiovascular Diseases.Curr Med Chem. 2009; 16(5): 550-563.
12.Mori N, Hirose T, Nakayama T,et al.Increased expression of urotensin II-related peptide and its receptor in kidney with hypertension or renal failure. Peptides. 2009 Feb;30(2):400-408.
13.Ong KL, Wong LY, Cheung BM. The role of urotensin II in the metabolic syndrome. Peptides. 2008 May;29(5):859-867.
14. Sun HX, Du WN, Zuo J, et al. The association of two single nucleotide polymorphisms in PRKCZ and UTS2 respectively with type 2 diabetes in Han people of northern China. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2002; 24:223-227.
15. Zhu F, Ji L, Luo B. The role of urotensin II gene in the genetic susceptibility to type 2 diabetes in Chinese population. Zhonghua Yi Xue Za Zhi 2002;82:1473-1475.
16. Suzuki S, Wenyi Z, Hirai M, et al. Genetic variations at urotensin II and urotensin II receptor genes and risk of type 2 diabetes mellitus in Japanese. Peptides 2004; 25:1803-1808.
17. Wenyi Z, Suzuki S, Hirai M, et al. Role of urotensin II gene in genetic susceptibility to type 2 diabetes mellitus in Japanese subjects. Diabetologia 2003;46:972-976.
18. Gonzalez A, Saez ME, Aragon MJ,et al. Specific haplotypes of the CALPAIN-5 gene are associated with polycystic ovary syndrome, Hum Reprod. 2006 Apr;21(4):943-951.
19. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
20. Matthews DR, Hosker JP, Rudenski AS,et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419
21. De Paula Martins W,Santana LF,Nastri CO et al. Agreement among insulin sensitivity indexes on the diagnosis of insulin resistance in polycystic ovary syndrome and ovulatory women. Eur J Obstet Gynecol Reprod Biol. 2007 ; 133:203-207.
22. Audrey C. Papp, Julia K,Pinsonneault.Single Nucleotide Polymorphism Genotyping Using Allele-Specific PCR and Fluorescence Melting Curves. Short Technical Report.2003,34:1068-1072.
23. Jun Wang, Karen Chuang, Mandeep Ahluwalia. High-throughput SNP genotyping by single-tube PCR with T_m-shift primers. Research Report.2005, 39:885-893.
24. San Millan JL, Corton M, Villuendas G, et al. Association of polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab 2004;89:2640-2646.
25. Du W, Sun H, Wang H, et al. Confirmation of susceptibility gene loci on chromosome 1 in northern China Han families with type 2 diabetes. Chin Med J 2001;114:876-878.
26. Mori Y, Otabe S, Dina C, et al. Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate Loci on 7p and11p. Diabetes 2002;51:1247—1255.
27. Leung Ong K,Wong L,Bun Man,et al.Haplotypes in the urotension II gene and urotension II receptor gene are associated with insulin resistance and impaired glucose tolerance.Peptides,2006,1659-1667.
28. Watson AM, Lambert GW, Smith KJ, et al. Urotensin II acts centrally to increase epinephrine and ACTH release and cause potent inotropic and chronotropic actions. Hypertension 2003;42:373-379.
29. Baron AD. Insulin resistance and vascular function. J Diabetes Complications, 2002, 16:92-102
30. Wilkes JJ, Hevener A, Olefsky J. Chronic endothelin-1 treatment leads to insulin resistance in vivo. Diabetes2003;52:1904-1909.
31.Wang K, You L, Shi Y,et al. Association of genetic variants of insulin degrading enzyme with metabolic features in women with polycystic ovary syndrome. Fertil Steril. 2008 Aug;90(2):378-384.
1. Orio F Jr, Pa;omba S, Di Biase S, et al. Homocysteine levels and C677T polymorphism of methylenetetrahydrofolate reductase in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003 ;88:673-679.
2. Kelestimur F, Unluhizarci K, Baybuga H, et al. Prevalence of polycystic ovarian changes and polycystic ovary syndrome in premenopausal women with treated type 2 diabetes mellitus. Fertil Steril 2006;86:405-410.
3. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005;83:1454-1460.
4. Pelusi B, Gambineri A, Pasquali R. Type 2 diabetes and the polycystic ovary syndrome. Minerva Ginecol 2004;56: 41-51.
5. Roldan B, San Millan JL, Escobar-Morreale HF. Genetic basis of metabolic abnormalities in polycystic ovary syndrome: implications for therapy. Am J Pharmacogenomics 2004;4: 93-107.
6. Jung CH, Rhee EJ,Kim SY. Associations between two single nucleotide polymorphisms of adiponectin gene and coronary artery diseases. Endocr J.2006 ; 53:671-7.
7. Nakatani K Noma K, Nishioka J. Adiponectin gene variation associates with the increasing risk of type 2 diabetes in non-diabetic Japanese subjects. Int J Mol Med.2005;15(1):173-177.
8.Menzaghi C, Ercolino T, Di Paola R et al. A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes 200251:2306-2312.
9. Gibson F, Froguel P. Genetics of the APM1 locus and its contribution to type 2 diabetes susceptibility in French Caucasians. Diabetes 2004;53:2977-2983.
10. Qi L, Li T, Rimm E et al .The +276 polymorphism of the APM1 gene, plasma adiponectin concentration, and cardiovascular risk in diabetic men. Diabetes 2005;54:1607-1610.
11. Zhang N,Shi YH, Hao CF,et al.Association of+45G15G(T/G) and +276(G/T) polymorphisms in the ADIPOQ gene with polycystic ovary syndrome among Han Chinese women.Eur J Endocrinol.2008,158(2):255-260
12. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006; 116:1784-1792.
13. Debard C, Laviue M, Berbe V, et al. Expression of key genes of fatty acid oxidation, including adiponectin receptors, in skeletal muscle of type 2 diabetic patients. Diabetologia 2004; 47:917-925.
14. Damcott CM,Ott SH,Pollin TI,et al.Genetic variation in adiponectin receptor 1 and adiponectin receptor 2 is associated with the old order Amish.Diabetes. 2005, 54(7);2245-2250
15. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
16. De Paula Martins W,Santana LF,Nastri CO et al. Agreement among insulin sensitivity indexes on the diagnosis of insulin resistance in polycystic ovary syndrome and ovulatory women. Eur J Obstet Gynecol Reprod Biol.2007 ; 133:203-207.
17. Matthews DR, Hosker JP, Rudenski AS,et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412—419
18. Audrey C. Papp, Julia K,Pinsonneault.Single Nucleotide Polymorphism Genotyping Using Allele-Specific PCR and Fluorescence Melting Curves. Short Technical Report.2003,34:1068-1072.
19. Jun Wang1, Karen Chuangl, Mandeep Ahluwalial . High-throughput SNP genotyping by single-tube PCR with T_m-shift primers. Research Report..2005, 39:885-893.
20. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-769.
21. Kharroubi l,Rasschaert J,Eizirik DL,et al.Expression of adiponectin receptors in pancreatic beta cells.Biochem Biophys Res Commun 2003,312:1118-1122.
22. Kadowaki T,Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome.J Clin Invest 2006 ; 116: 1784-1792.
23. Bluher M, Bullen JW Jr, Lee JH, Kralisch S, Fasshauer M, Kloting N, Niebauer J, Schon MR, Williams CJ, Mantzoros CS: Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle: associations with metabolic parameters and insulin resistance and regulation by physical training. J Clin Endocrinol Metab 2006,91:2310-2316.
24. Tan BK, Chen J, Diaby JE, et al. Upregulation of adiponectin receptor 1 and 2 mRNA and protein in adipose tissue and adipocytes in insulin-resistant women with polycystic ovary syndrome.Diabetologia 2006 Nov;49(11):2723-2728.
25. Vink JM,Sadrzadeh S,Lambalk CB et al. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab 2006;91:2100-2104.
26. Brenda L. Powell, Lema Haddad, Amanda Bennett, Analysis of multiple data sets reveals no association between the insulin gene variable number tandem repeat element and polycystic ovary syndrome or related traits. J Clin Endocrinol Metab. 2005 ;90:2988-2993.
27. Lu Q, Doria A, Giorgi E, et al.V ariation in adiponectin receptor genes and susceptibility to type 2 diabetes in women. Diabetes 2007,56:1586-1591
28. Ruchat SM, Loose RJ, Rankinen T,et al. Associations between glucose tolerance,insulin sensitivity and insulin secretion phenotypes and polymorphisms in adiponectin and adiponectin receptor genes in the Quebec Family Study.Diabet Med 2008, 25:400-406.
29. Siitonen N,Pulkkien L,Maqeru,et al.Association of sequence variations in the gene encoding adiponectin receptor 1(ADIPOR1) with body size and insulin levels.The Finnish Diabetes Prevention Study.Diabetologia.2006,49:1795-805.
30. Hu C, Jia WP,Zhang R,et al.Relationship between adiponectin receptor 1 gene -3881T/C variant and glucose metabolism in the Chinese. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2007 ;24:27-30.
31. Collins SC,Luan J,Thompson AJ,et al.Adiponectin receptor genes: mutation screening in syndromes of insulin resistance and association studies for type 2 diabetes and metabolic traits in UK populations. Diabetologia 2007 ;50:555-562.
32. Haddad L,Evans JC,Gharani N,et al.Variation within the type 2 diabetes susceptibility gene calpain-10 and polycystic ovary syndrome. J Clin Endocrinol Metab.2002 ;87:2606-2610.
33. Stefan N,Machicao F,Staiger H,et al. Polymorphisms in the gene encoding adiponectin receptor 1 are associated with insulin resistance and high liver fat. Diabetologoa 2005 ;48:2282-2291.